Current status of new drug development approved by FDA: fasenra

Source: ACS American Chemical Society 2017-11-28 US FDA approved the AstraZeneca drug fasenra (benralizumab) on November 14, 2017 Eastern time to give additional maintenance treatment to severe asthma patients with eosinophils aged 12 years and over Asthma is the abbreviation of asthma Asthma is a chronic inflammatory disease of the airway, which involves many kinds of cells (such as eosinophils, mast cells, T lymphocytes, neutrophils, airway epithelial cells, etc.) and cell components This kind of chronic inflammation leads to the production of airway hyperresponsiveness, usually presents a wide range of reversible airflow restriction, and causes recurrent symptoms such as wheezing, shortness of breath, chest tightness or cough It often occurs at night and / or in the early morning, and most patients can relieve themselves or slow down after treatment ( Com) Pascal soriot, CEO of AstraZeneca, said: "we are pleased to be able to provide fasenra as a new precise biotherapy drug to help improve the lives of patients with severe asthma accompanied by eosinophils This is the first approved product of our respiratory biopharmaceutics and the latest in a series of milestones in our product innovation and transformation process " So who is studying fasenra in the world? Is there any research and development institution in China already doing research on it? Which countries and regions are the patents distributed to? What technical information does AstraZeneca have in its patents? Let's get it from STN, the world famous online retrieval system of scientific and technological information! (search date: November 17, 2017) when was fasenra disclosed? Who is doing research on fasenra in the world? At present, the global patent application agencies apply for fasenra's patent layout? Technical information of AstraZeneca's patents on fasenra